Therapeutic Class

Abecma clocks $164m for Bristol-Myers but supply constraints remain

Abecma clocks $164m for Bristol-Myers but supply constraints remain Abecma clocks $164m for Bristol-Myers but supply constraints remain

Bristol-Myers Squibb says it expects viral vector supply to ramp up later in the year as third-party and inhouse capacity come online.

byDan Stanton, Editorial director

Feb 7, 2022

|

1 Min Read

Oxford Biomedica enters US through $180m Homology JV

Oxford Biomedica enters US through $180m Homology JV Oxford Biomedica enters US through $180m Homology JV

Jan 31, 2022

1 Min Read

Biogen pulling out of Bioepis JV in $2.3bn Samsung Bio deal

Biogen pulling out of Bioepis JV in $2.3bn Samsung Bio deal Biogen pulling out of Bioepis JV in $2.3bn Samsung Bio deal

Jan 31, 2022

1 Min Read

2021 CGT moments: First place for second line CAR-T

2021 CGT moments: First place for second line CAR-T 2021 CGT moments: First place for second line CAR-T

byMillie Nelson

Jan 31, 2022

1 Min Read

CDMO Arranta buys Cytiva single-use tech for mRNA production

Upstream & Downstream Processing

CDMO Arranta buys Cytiva single-use tech for mRNA production CDMO Arranta buys Cytiva single-use tech for mRNA production

byGareth Macdonald

Jan 27, 2022

1 Min Read

Novartis looks to gene therapy 3.0 with an eye on lowering COGS

Therapeutic Class

Novartis looks to gene therapy 3.0 with an eye on lowering COGS Novartis looks to gene therapy 3.0 with an eye on lowering COGS

Jan 26, 2022

1 Min Read

Excellos: ‘There is no better time to enter cell therapy CDMO space’

Therapeutic Class

Excellos: ‘There is no better time to enter cell therapy CDMO space’

Excellos: ‘There is no better time to enter cell therapy CDMO space’

byDan Stanton, Editorial director

Limula on the future of cell therapies: Closed, automated, decentralized

Therapeutic Class

Limula on the future of cell therapies: Closed, automated, decentralized

Limula on the future of cell therapies: Closed, automated, decentralized

byDan Stanton, Editorial director

CBM and UPenn enter gene therapy manufacturing pact

CBM and UPenn enter gene therapy manufacturing pact

CBM and UPenn enter gene therapy manufacturing pact

byDan Stanton, Editorial director

Lonza teams with Agilent to make cell therapy Cocoon platform ‘smarter’

Therapeutic Class

Lonza teams with Agilent to make cell therapy Cocoon platform ‘smarter’

Lonza teams with Agilent to make cell therapy Cocoon platform ‘smarter’

byDan Stanton, Editorial director

With acquisitions integrated, Curia unveils mRNA offering

Therapeutic Class

With acquisitions integrated, Curia unveils mRNA offering

With acquisitions integrated, Curia unveils mRNA offering

byDan Stanton, Editorial director

Cell and gene therapy exits from Sanofi and AvroBio

Therapeutic Class

Cell and gene therapy exits from Sanofi and AvroBio

Cell and gene therapy exits from Sanofi and AvroBio

byDan Stanton, Editorial director

Amgen: Not treating biosimilars as ‘stepchild’ is key to success

Amgen: Not treating biosimilars as ‘stepchild’ is key to success

Amgen: Not treating biosimilars as ‘stepchild’ is key to success

byDan Stanton, Editorial director

New year, new gene therapy plants from Pfizer and Expression

Facilities & Capacity

New year, new gene therapy plants from Pfizer and Expression

New year, new gene therapy plants from Pfizer and Expression

byDan Stanton, Editorial director

Novartis to boost gene therapy pipeline through $800m Gyroscope buy

Therapeutic Class

Novartis to boost gene therapy pipeline through $800m Gyroscope buy

Novartis to boost gene therapy pipeline through $800m Gyroscope buy

byDan Stanton, Editorial director

RNA sector set for progress thanks to decades long research drive

Therapeutic Class

RNA sector set for progress thanks to decades long research drive

RNA sector set for progress thanks to decades long research drive

byGareth Macdonald

BrainStorm’s cell therapy: Catalent high on NurOwn supply

BrainStorm’s cell therapy: Catalent high on NurOwn supply

BrainStorm’s cell therapy: Catalent high on NurOwn supply

byDan Stanton, Editorial director

Internal capabilities ‘the backbone’ of Pfizer’s gene therapy strategy

Therapeutic Class

Internal capabilities ‘the backbone’ of Pfizer’s gene therapy strategy

Internal capabilities ‘the backbone’ of Pfizer’s gene therapy strategy

byDan Stanton, Editorial director

WuXi ATU opens Philly cell and gene therapy testing center

Therapeutic Class

WuXi ATU opens Philly cell and gene therapy testing center

WuXi ATU opens Philly cell and gene therapy testing center

byGareth Macdonald

Doggybone DNA ‘ideal tech’ for pandemic vaccine response, says Touchlight

Therapeutic Class

Doggybone DNA ‘ideal tech’ for pandemic vaccine response, says Touchlight

Doggybone DNA ‘ideal tech’ for pandemic vaccine response, says Touchlight

byDan Stanton, Editorial director

Regeneron moving fast to assess Ab cocktail for Omicron variant

Therapeutic Class

Regeneron moving fast to assess Ab cocktail for Omicron variant

Regeneron moving fast to assess Ab cocktail for Omicron variant

byDan Stanton, Editorial director

Scaling-up AAV production? Take your time to develop best processes

Upstream & Downstream Processing

Scaling-up AAV production? Take your time to develop best processes

Scaling-up AAV production? Take your time to develop best processes

byDan Stanton, Editorial director

Novo Nordisk to add RNAi engine in $3.3bn Dicerna buy

Therapeutic Class

Novo Nordisk to add RNAi engine in $3.3bn Dicerna buy

Novo Nordisk to add RNAi engine in $3.3bn Dicerna buy

byDan Stanton, Editorial director

eBook: Vaccines Revisited — The Past, Present, and Future of Nucleic-Acid Vaccine Production

Therapeutic Class

eBook: Vaccines Revisited — The Past, Present, and Future of Nucleic-Acid Vaccine Production

eBook: Vaccines Revisited — The Past, Present, and Future of Nucleic-Acid Vaccine Production

+1

byDan Stanton, Millie Nelsonand 1 more

List forks out $125m+ for microbiome Indiana plant

Therapeutic Class

List forks out $125m+ for microbiome Indiana plant

List forks out $125m+ for microbiome Indiana plant

byMillie Nelson, Editor

Podcast: Life beyond Provenge as Dendreon enters CDMO world

Therapeutic Class

Podcast: Life beyond Provenge as Dendreon enters CDMO world

Podcast: Life beyond Provenge as Dendreon enters CDMO world

byDan Stanton, Editorial director

Regeneron says tech was key to rapid COVID-19 mAb cocktail dev

Therapeutic Class

Regeneron says tech was key to rapid COVID-19 mAb cocktail dev

Regeneron says tech was key to rapid COVID-19 mAb cocktail dev

byGareth Macdonald

Quality gene therapies require quality analytics

Therapeutic Class

Quality gene therapies require quality analytics

Quality gene therapies require quality analytics

byGareth Macdonald

J&J preps to enter cell therapy space as CAR-T approval decision approaches

Therapeutic Class

J&J preps to enter cell therapy space as CAR-T approval decision approaches

J&J preps to enter cell therapy space as CAR-T approval decision approaches

byDan Stanton, Editorial director

Boehringer’s adalimumab becomes first interchangeable mAb biosimilar

Boehringer’s adalimumab becomes first interchangeable mAb biosimilar

Boehringer’s adalimumab becomes first interchangeable mAb biosimilar

byDan Stanton, Editorial director

Room for both allogeneic and autologous in cell therapy space

Therapeutic Class

Room for both allogeneic and autologous in cell therapy space

Room for both allogeneic and autologous in cell therapy space

byGareth Macdonald

Avid turns to viral vector production on back of strong CGT growth

Facilities & Capacity

Avid turns to viral vector production on back of strong CGT growth

Avid turns to viral vector production on back of strong CGT growth

byDan Stanton, Editorial director

Sponsored Content

Standardized AAV manufacturing: Why are AAV reference materials needed?

Standardized AAV manufacturing: Why are AAV reference materials needed?

byVigene Biosciences

Iovance opens PA cell therapy plant; produces first batch of lifileucel

Facilities & Capacity

Iovance opens PA cell therapy plant; produces first batch of lifileucel

Iovance opens PA cell therapy plant; produces first batch of lifileucel

byDan Stanton, Editorial director

Gilead: ‘Cell therapy is at the very early stages of its penetration’

Therapeutic Class

Gilead: ‘Cell therapy is at the very early stages of its penetration’

Gilead: ‘Cell therapy is at the very early stages of its penetration’

byDan Stanton, Editorial director

Subscribe to receive our monthly print or digital publication

Join our 70,000+ readers. And yes, it's completely free.